US at a glance
- Population
- 341.8 million 2025
- Life expectancy at birth
- 78.9 years, 2024
- People aged 65 and over
- 18.4 % of people, 2025
- Health spending per person
- 13,473 US$ per person, 2023
- Doctors
- 3.68 per 1,000 people, 2022
US Travel Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Disease, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $2.12 Bn.
Canada at 7.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.25 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.01 Bn | — | — |
| 2025 (base) | $2.12 Bn | +$106.6 Mn | — |
| 2026 (forecast) | $2.23 Bn | +$112.3 Mn | +5.3% |
| 2027 (forecast) | $2.35 Bn | +$118.2 Mn | +10.9% |
| 2028 (forecast) | $2.47 Bn | +$124.5 Mn | +16.8% |
| 2029 (forecast) | $2.60 Bn | +$131.1 Mn | +22.9% |
| 2030 (forecast) | $2.74 Bn | +$138.0 Mn | +29.5% |
| 2031 (forecast) | $2.89 Bn | +$145.4 Mn | +36.3% |
| 2032 (forecast) | $3.04 Bn | +$153.1 Mn | +43.5% |
| 2033 (forecast) | $3.20 Bn | +$161.2 Mn | +51.2% |
| 2034 (forecast) | $3.37 Bn | +$169.7 Mn | +59.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$2.12 Bn
Canada
$389.1 Mn
China
$349.6 Mn
Japan
$308.1 Mn
Germany
$155.3 Mn
UK
$125.8 Mn
France
$108.4 Mn
Brazil
$106.9 Mn
Spain
$95.9 Mn
Italy
$94.6 Mn
Ecuador
$93.7 Mn
India
$86.4 Mn
Saudi Arabia
$83.7 Mn
Mexico
$68.2 Mn
Australia
$57.3 Mn
Russia
$47.8 Mn
New Zealand
$46.5 Mn
South Africa
$30.7 Mn
UAE
$24.2 Mn
Egypt
$13.3 Mn
Philippines
$10.1 Mn
Hong Kong
$8.5 Mn
Malaysia
$6.7 Mn
Singapore
$6.4 Mn
Thailand
$4.7 Mn
Kenya
$3.1 Mn
| Market size, 2025 | $2.12 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.37 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease, channel and end user (see all) |
| Key players | Sanofi, Valneva, Bavarian Nordic, GSK PLC, Bharat Biotech (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Travel vaccines protect travellers against diseases common in other regions, such as typhoid, yellow fever, rabies and cholera.
Key segments of the travel Vaccines market include disease (Typhoid, Yellow Fever and Rabies) and channel (Travel Clinics, Pharmacies and Hospitals).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the travel Vaccines market.
New vaccines, rapid tests and public-private funding for neglected diseases give the travel Vaccines market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the travel Vaccines market.
The travel Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for travel Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Travel Vaccines right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
Medical Devices · US
Medical Devices · US
OTC & Nutraceuticals · US
Medical Devices · US
Healthcare Services · US
Medical Devices · US